These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 506182)

  • 1. [Immunity indices in patients with cancer of the uterine body treated with 17-alpha-oxyprogesterone-capronate].
    Iatskovskaia NL
    Vopr Onkol; 1979; 25(10):53-5. PubMed ID: 506182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunological reactivity of the body in cancer of the corpus uteri].
    Gorodilova VV; Iatskovskaia NL
    Vopr Onkol; 1978; 24(3):10-3. PubMed ID: 644958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of hydroxyprogesterone caproate on immunological skin tests and on the T-lymphocytes in cancer of the corpus uteri].
    Krylova NV; Mar'enko AI; Kondrat'ev VB; Bobrov IuF; Bokhman IaV
    Vopr Onkol; 1980; 26(3):30-2. PubMed ID: 6966107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Synthetic progestins in combined treatment of cancer of the uterine body].
    Iatskovskai NL
    Vopr Onkol; 1976; 22(3):25-8. PubMed ID: 936523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Description of some cases of mammary and uterine carcinoma treated with hydroxyprogesterone capronate].
    Barnaba T
    Minerva Ginecol; 1970 Oct; 22(19):957-63. PubMed ID: 5515156
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunologic reactions in cervical cancer].
    Gorodilova VV; Iatskovskaia NL
    Vopr Onkol; 1977; 23(3):9-12. PubMed ID: 898800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of 17-alpha-hydroxprogesterone-capronate in certain malignant tumors].
    Garin AM; Voznyĭ EK; Borisov VI; Dobrushina VA; Lazovskaia EB
    Klin Med (Mosk); 1974 Mar; 52(3):121-3. PubMed ID: 4466932
    [No Abstract]   [Full Text] [Related]  

  • 8. [Central mechanism of the action of 17-alpha-hydroxy-progesterone capronate in the treatment of endometrial cancer].
    Krylova NV; Bokhman IaV; Chepik OF; Dil'man VM
    Akush Ginekol (Mosk); 1977 Sep; (9):50-3. PubMed ID: 596564
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of thymalin in the complex treatment of patients with cancer of the uterus].
    Bakhidze EV; Bokhman IaV; Khavinson VKh; Morozov VG
    Vopr Onkol; 1985; 31(8):56-61. PubMed ID: 3839953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of hormone therapy in the treatment of cancer of the endometrium].
    Vekhova LI; Shuvaeva NI; Malysheva SF; Lebedeva AV
    Vopr Onkol; 1983; 29(3):26-30. PubMed ID: 6836983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular and humoral immunity in women with endometrial cancer].
    Bernt T; Janković D; Vecek N
    Jugosl Ginekol Perinatol; 1987; 27(1-2):7-10. PubMed ID: 3682895
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies on the immune status of patients with operated and irradiated cervical and breast cancer. III. Comparative investigation of the immune status of patients with breast cancer treated by operation and irradiation and of patients with cervical cancer treated either by operation or irradiation (author's transl)].
    Palencia C; Wicke L; Kärcher KH; Gitsch E; Hernuss P; Steffen C
    Wien Klin Wochenschr; 1976 Aug; 88(15):495-501. PubMed ID: 997530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of 19-nor-17 alpha-hydroxyprogesterone caproate in endometrial cancer].
    Márquez J; Dabancens A; González O; Rosmanich A
    Rev Chil Obstet Ginecol; 1976; 41(5):304-11. PubMed ID: 1030512
    [No Abstract]   [Full Text] [Related]  

  • 15. [Functional indices of the peripheral blood lymphocytes in gynecologic patients].
    Stepankovskaia GK; Senchuk AIa; Iarotskiĭ NE
    Vrach Delo; 1989 Oct; (10):81-3. PubMed ID: 2617996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of hydroxyprogesterone caproate and its combination with tamoxifen on steroid hormone receptors in the tumor and on the basic parameters of reproductive homeostasis in patients with cancer of the corpus uteri].
    Vishnevskiĭ AS; Bokhman IaV; Tsyrlina EV; Bobrov IuF; Shtofmakher IA
    Vopr Onkol; 1989; 35(9):1063-7. PubMed ID: 2815695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Variation of the immune response in patients with cancer].
    Barboni F; Rovinetti C; Nubile G; Zulli P; Mariani G
    Boll Soc Ital Biol Sper; 1976 Jun; 52(12):899-905. PubMed ID: 1023903
    [No Abstract]   [Full Text] [Related]  

  • 18. [Action of 17-hydroxyprogesterone caproate on the glandular hyperplasia of human endometrium].
    Lukina EL; Prianishnikov VA
    Arkh Patol; 1978; 40(3):45-50. PubMed ID: 646674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oxyprogesterone capronate in the treatment of menstrual epilepsy].
    Badalian LO; Temin PA; Mukhin KIu
    Ross Med Zh; 1992; (3):41-4. PubMed ID: 1643360
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of oxyprogesterone caproate, tamoxifen and their combination on the level of steroid hormone receptors in the tumor, and some parameters of the reproductive system in patients with endometrial cancer.
    Vishnevsky AS; Shtofmakher JA; Bokhman JV; Tsyrlina EV; Bobrov JF; Chepick OF; Sofroniy DF
    Clin Exp Obstet Gynecol; 1990; 17(3-4):159-62. PubMed ID: 2127240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.